

2017-05-16

Boule Diagnostics optimizes the manufacturing structure – shuts down the Chinese production facility

Boule's process efficiency program continues. As a result of this, the manufacturing of instruments will in the future be concentrated to the Swedish production facility. A decision has therefor been made during the second quarter of 2017 to discontinue the Chinese production facility. The facility currently employs 13 people.

By concentrating the production of instruments to one production unit, Boule will cut costs by an estimated SEK 3 million annually and streamline internal processes. This will also allow Boule to decrease its working capital. The total cost associated with closing the facility will be SEK 3 million and the cost will be recognized in the second quarter of 2017.

"In line with our previous communicated ambition to optimize and streamline our manufacturing structure, we have decided to close our manufacturing operations in China. The decision will not affect our commercial strategies in Asia, where we expect a continued strong sales growth.", says Fredrik Dalborg, CEO and Group President of Boule Diagnostics.

For further information, please contact:

Fredrik Dalborg, CEO and Group President, Boule Diagnostics AB, phone +46 705 58 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is one of the few companies on the global diagnostics market that develops, manufactures and markets instruments and consumable products for blood diagnostics under its own direction. The company serves hospitals, clinics, laboratories and companies within blood diagnostics of both human and veterinary hematology. The group has an annual sale of slightly above SEK 400 million and around 170 employees. Sales are made via distributors in over 100 countries and directly in Sweden and the USA. The company operates via subsidiary operating companies in Sweden, USA and China. Since 2011, Boule shares have been listed on the Nasdaq Stockholm.

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 09:15 May 16, 2017.